OPEN ACCESS Freely available online

ISSN: 2157-7560
Journal of
Vaccines & Vaccination

Short Communication

Vaccination Strategies for Zoonotic Diseases: Advancing Protection across Human and Animal Populations

Camelia Truce*

Department of Economics Laboratories d'Économie d'Orléans (LEO), CNRS, Economics and Management, University of Orleans, Orleans, France

DESCRIPTION

Zoonotic diseases are infections that can pass between animals and humans through direct contact, contaminated environments, food products, insect vectors, or exposure to infected wildlife. These diseases have influenced public health for centuries and continue to affect communities worldwide. Rabies, brucellosis, leptospirosis, avian influenza, and several viral hemorrhagic fevers demonstrate the diverse nature of zoonotic pathogens and their ability to affect both animal and human populations. Vaccination remains one of the most effective methods for reducing disease transmission, lowering mortality rates, and limiting the economic burden associated with outbreaks.

The development of vaccines against zoonotic diseases requires an understanding of the interactions among pathogens, animal hosts, environmental conditions, and human behaviour. Unlike vaccines designed solely for human diseases, zoonotic disease vaccines often involve coordinated programs targeting animals as well as people. In many situations, preventing infection in animals can substantially reduce the likelihood of transmission to humans. This approach has been demonstrated in rabies control programs, where vaccination of domestic dogs has significantly reduced human cases in several regions.

Modern vaccine research has expanded beyond traditional formulations. Scientists now employ a variety of technologies including inactivated vaccines, live attenuated vaccines, recombinant protein vaccines, viral vector platforms, and nucleic acid-based approaches. Each method offers distinct advantages depending on the biological characteristics of the pathogen. Vaccine selection is influenced by factors such as safety, duration of immunity, manufacturing requirements, storage conditions, and expected field performance.

Rabies vaccination represents one of the most successful examples of zoonotic disease prevention. Mass vaccination campaigns targeting dogs have resulted in substantial declines in human rabies deaths in many countries. Human vaccines remain available for post-exposure treatment and for individuals at elevated occupational risk. The combined use of animal vaccination, public education, and surveillance programs has produced measurable improvements in disease control.

Livestock vaccination also plays an important role in reducing zoonotic disease transmission. Diseases such as brucellosis can affect cattle, sheep, and goats while also causing chronic illness in humans. Vaccination programs in animal populations have contributed to lower infection rates and improved agricultural productivity. Similar approaches are used to control other bacterial and viral infections that circulate among domestic animals and occasionally spread to people.

Wildlife vaccination has emerged as an additional component of disease management. Oral vaccine baits have been used in selected regions to reduce rabies transmission among wild carnivores. Such programs require careful ecological planning, distribution strategies, and long-term monitoring to evaluate effectiveness. Wildlife vaccination initiatives may help reduce pathogen circulation in natural reservoirs while minimizing risks to nearby human communities and domestic animals.

The appearance of newly recognized zoonotic pathogens has increased interest in rapid vaccine development. Global travel, urban expansion, environmental modification, and changing interactions between humans and animals can create conditions that facilitate disease emergence. Public health agencies and research institutions therefore emphasize preparedness measures that include vaccine platform development, pathogen surveillance, and coordinated response planning. The ability to adapt existing vaccine technologies to newly identified pathogens may support faster responses during outbreaks.

CONCLUSION

Zoonotic diseases continue to present significant public health and veterinary challenges across many parts of the world.

Correspondence to: Camelia Truce, Department of Economics Laboratories d'Économie d'Orléans (LEO), CNRS, Economics and Management, University of Orleans, Orleans, France Email: camelia.turcu@univ-orleans.fr

Received: 29-Sep-2025, Manuscript No JVV-25-31769; **Editor assigned:** 01-Oct-2025, PreQC JVV-25-31769 (PQ); **Reviewed:** 15-Oct-2025, QC No. JVV-25-31769; **Revised:** 22-Oct-2025, Manuscript No. JVV-25-31769 (R); **Published:** 29-Oct-2025, DOI: 10.35248/2157-7560.25.16.627.

Citation: Truce C (2025) Vaccination Strategies for Zoonotic Diseases: Advancing Protection across Human and Animal Populations. J Vaccines Vaccin. 16:627.

Copyright: © 2025 Truce C. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Vaccines provide a practical means of reducing transmission, protecting vulnerable populations, and supporting animal health. Through coordinated efforts involving scientific research, surveillance, public education, and vaccination programs, it is possible to reduce the impact of zoonotic infections and strengthen overall health security. Continued attention to vaccine development and implementation will contribute to safer interactions between humans and animals while supporting long-term disease control objectives.

REFERENCES

1. Gupta S, Kaur R, Sohal JS, Singh SV, Das K, Sharma MK, et al. Countering zoonotic diseases: Current scenario and advances in diagnostics, monitoring, prophylaxis and therapeutic strategies. Arch Med Res. 2024;55(6):103037.
2. Li H, Kim S, Machalaba C. Human-animal interfaces and zoonotic disease risks in China: a review of contact behaviors and risk communication. Sci One Health. 2026:100153.
3. Hernández M, Caltempa AO, Villalobos N, Elizondo MC, Guzman C, Hernández-Accedes JA, et al. Novel Oral papaya-based preventive and therapeutic vaccine for controlling different zoonotic Taeniid parasites: Current advances. Vaccine. 2025;66:127818.
4. Worsley-Tonks KE, Abakar MF, Coulibaly Z, Deya-Yang MP, Esso L, Feussom JM, et al. Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Cameroon, Chad, Côte d'Ivoire, and Mali. Lancet Infect Dis. 2026;26(4):e245-258.
5. Pantha S, Subedi D, Jyoti S, Shrestha SP, Ghimire TR, Acharya KP. Zoonotic diseases in low and middle-income countries (LMICs): Economic burden, challenges, strategies, and future directions. Anim. Zoonoses. 2025.
6. Rajpoot P, Singh M, Shakya M, Sharma AK, Bhangale GN, Mourya A, et al. Percent positivity and risk analysis of zoonotic intestinal parasites (helminths) in dogs population-a participatory epidemiological study. Vet Parasitol Reg Stud Reports. 2026:101443.
7. Liu JS, Li XC, Zhang QY, Han LF, Xia S, Kassegne K, et al. China's application of the One Health approach in addressing public health threats at the human-animal-environment interface: Advances and challenges. One Health. 2023;17:100607.
8. Mohammad MR, Moradkasani S, Latifian M, Esmaeili S. Coxiella burnetii: emerging threats, molecular insights, and advances in diagnosis and control measures. J Microbiol Methods. 2025:107213.
9. Lam JY, Yuen CK, Cheung SK, Cheung PH, Yuen KY, Kok KH. Nasal RNA-scaffold-protein vaccine protects mice from human H5N1 clade 2.3. 4.4 b virus lethal infection and safeguards against vaccine-unmatched viruses. Ebiomedicine. 2026;126.
10. Zinsstag J, Kaiser-Grolimund A, Heitz-Tokpa K, Sreedharan R, Lubroth J, Caya F, et al. Advancing one human-animal-environment health for global health security: what does the evidence say?. Lancet. 2023;401(10376):591-604.